Teriparatide is marketed under the brand name Forteo [1].
Who Makes Forteo?
Forteo is manufactured by Eli Lilly and Company [2].
What Is Teriparatide Used For?
Teriparatide, sold as Forteo, is a form of parathyroid hormone used to treat osteoporosis in postmenopausal women at high risk for fracture [1]. It is also used to increase bone mass in men and women with primary or postmenopausal osteoporosis who are at high risk for fracture and for whom other treatments are not suitable [1]. Additionally, Forteo is prescribed to increase bone mass in men and women with bone fractures, osteoporosis, or osteopenia who are at high risk for fractures [1].
How Does Forteo Work?
Forteo stimulates bone formation, which helps to build new bone and increase bone density [3]. It is a form of parathyroid hormone (PTH) that works by increasing osteoblast (bone-building cells) activity while decreasing osteoclast (bone-resorbing cells) activity [3].
When Does Forteo Patent Expiration Occur?
The patent landscape for teriparatide products can be complex, involving multiple patents covering the drug itself, its formulations, and methods of use [4]. Information on specific patent expiry dates for Forteo can be found on specialized resources like DrugPatentWatch.com, which tracks pharmaceutical patent information [4].
Are There Other Brands of Teriparatide?
Following patent expiries and regulatory pathways, generic versions of teriparatide are available [5]. These generic products are typically marketed under their active ingredient name, teriparatide, by various pharmaceutical manufacturers [5].
What are the Risks Associated with Teriparatide?
A significant safety concern associated with teriparatide is an increased risk of osteosarcoma, a rare bone cancer. This risk was observed in studies on rats, and its relevance to humans is not fully established [1]. However, teriparatide should not be used in patients with a history of bone cancer, Paget's disease of bone, unexplained elevations of alkaline phosphatase, or skeletal metastases or Jeżeli the patient has bone cancer [1]. Other potential side effects include nausea, joint pain, and dizziness [1].
How Does Teriparatide Compare to Other Osteoporosis Treatments?
Teriparatide is considered a bone-building agent, working differently than antiresorptive drugs like bisphosphonates (e.g., alendronate, risedronate) which primarily slow bone loss [3]. Teriparatide's anabolic action can lead to significant increases in bone mineral density, particularly in the spine [3]. Its use is generally reserved for patients with severe osteoporosis or those who have not responded to other treatments due to its specific risk profile and administration requirements (daily injection) [3].
What is the Cost of Teriparatide?
The cost of teriparatide, both brand-name Forteo and its generic equivalents, can be substantial due to its nature as a biologic drug and the associated manufacturing and research expenses [6]. Pricing varies based on dosage, quantity, and insurance coverage [6].
Can Biosimilars of Teriparatide Be Developed?
As teriparatide is a protein-based drug, the development of biosimilars is a possibility [7]. Biosimilars are highly similar to approved biologic medicines, with no clinically meaningful differences in safety or efficacy [7]. Regulatory pathways exist for the approval of teriparatide biosimilars, which could increase treatment options and potentially lower costs [7].
What Clinical Data Supports Teriparatide's Efficacy?
Clinical trials have demonstrated that teriparatide significantly reduces the risk of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis [1]. Studies have shown increases in bone mineral density at the lumbar spine and hip in patients treated with teriparatide compared to placebo [1].
Patient Concerns Regarding Teriparatide Treatment
Patients often inquire about the administration of daily injections, potential side effects like nausea and dizziness, and the long-term safety profile, particularly concerning the risk of osteosarcoma [1]. Discussions with healthcare providers typically address these concerns, along with treatment duration and monitoring [1].
Sources:
[1] https://www.drugs.com/forteo.html
[2] https://www.lilly.com/products/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3905810/
[4] https://drugpatentwatch.com/
[5] https://www.goodrx.com/teriparatide
[6] https://www.ncbi.nlm.nih.gov/books/NBK559141/
[7] https://www.fda.gov/vaccines-blood-biologics/science-and-research-biologics/biosimilars